Scribe Therapeutics
13 articles with Scribe Therapeutics
-
Scribe Therapeutics to Participate in Four Upcoming Conferences
11/17/2022
Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, announced it will participate in four upcoming conferences.
-
Scribe Therapeutics to Participate in Upcoming Investor Conferences - September 29, 2022
9/29/2022
Scribe Therapeutics Inc. announced it will participate in two upcoming investor conferences: Scribe co-founder and CEO Benjamin Oakes will participate in a panel titled “Gene Editing: Next-Generation Technologies Worth Watching,” at 9:30 a.m. ET on Oct. 3, 2022, at the Chardan Genetic Medicines Conference in New York, NY.
-
Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
9/27/2022
Scribe Therapeutics Inc. today announced a strategic collaboration with Sanofi for the use of Scribe’s CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.
-
Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.
-
This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.
-
Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires
7/26/2022
Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, announced the expansion of its headquarters and addition of three vice presidents to its growing management team.
-
Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect
7/15/2022
Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the virtual Biopharma Private Company Connect event hosted by SVB Securities on July 20-21, 2022.
-
Scribe Therapeutics Expands Collaboration With Biogen to Second Target
5/2/2022
Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, announced Biogen Inc. (Nasdaq:BIIB) has exercised an option for an additional disease target in gene therapy as part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based medicines.
-
Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
4/1/2022
Scribe Therapeutics Inc. today announced its participation in the Goldman Sachs The New Guard: Privates Leading The Disruption In Healthcare conference.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
April springs up with showers of cash for these life sciences companies.
-
Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines
3/31/2021
Molecular engineering company’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of disease
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.